Patent · US Active

Anti-ERBB3 antibodies

US10494441B2 · kind B2 · utility

3Cited by

9References

7Claims

0Family size

Assignee

AVEO Pharmaceuticals, Inc. · US

Inventors

Sylvie Vincent · Somerville, US
William M. Winston, Jr. · Marlborough, US
Fang Wang · Fujian, CN
Solly Weiler · Newton, US
Kristan Meetze · Lexington, US
Lyne Breault · Brookline, US
Steve Bottega · Cambridge, US
Ting Chen · Austin, US
Michael DePrima · Somerville, US
Christina Fleet · Melrose, US
Steven Tyler · Boston, US
Jin-Kyeung Woo · Newton, US
Jeno Gyuris · Lincoln, US

Key dates

Filing date	Mar 2, 2017
Grant date	Dec 3, 2019
Priority date	—
Expiry date	Mar 2, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/63
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.